KENILWORTH, N.J., March 22 /PRNewswire/ -- Schering-Plough Corporation today announced that Susan G. Arbuck, M.D., has been appointed vice president, oncology, global clinical development, for the Schering-Plough Research Institute. She is based in Kenilworth, N.J., and reports to Peder K. Jensen, M.D., executive vice president, global clinical development.
In this role, Arbuck is responsible for the global clinical development of oncology products and represents the global clinical development group on an internal product development committee.
Arbuck recently held the position of vice president and global head of the oncology therapeutic area at Aventis Pharmaceuticals. She is the former head of the Developmental Chemotherapy Section at the National Cancer Institute (NCI). During her career, she contributed to the development and registration of many approved oncology products. She provided leadership in cancer drug development through other efforts, including the development of standardized criteria for adverse event and tumor response reporting, which are used internationally in oncology clinical trials. She also contributed to the development of novel trial designs and strategies to increase the efficiency of cancer drug development and registration.
Arbuck has 10 years experience participating with the FDA in monthly FDA National Cancer Institute working group meetings. She served as a visiting professor at the National Cancer Center in Tokyo, Japan, and has participated in a workshop with The European Agency for the Evaluation of Medicinal Products (EMEA). Arbuck is a board-certified medical oncologist who has served on various committees for the American Association for Cancer Research and American Society of Clinical Oncology. She has more than 100 peer- reviewed publications. She holds a B.Sc. from the University of Toronto, a M.Sc. in Pharmacology from the State University of New York at Buffalo and an M.D. from McMaster University Medical School in Hamilton, Ontario.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com/ .
CONTACT: Media: Rosemarie Yancosek, +1-908-298-7476; Investor: JanetBarth, or Alex Kelly, +1-908-298-7436, all of Schering-Plough Corporation